Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer (LABC/MBC) in adults whose disease has progressed after at least two chemotherapy regimens. The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Halaven(®); Eisai...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoecon Open
Autors principals: Fleeman, Nigel, Bagust, Adrian, Duarte, Rui, Richardson, Marty, Nevitt, Sarah, Boland, Angela, Kotas, Eleanor, McEntee, Joanne, Thorp, Nicky
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2019
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6710448/
https://ncbi.nlm.nih.gov/pubmed/30742256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-018-0114-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars